195 related articles for article (PubMed ID: 30779990)
1. Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis.
Younossi ZM; Stepanova M; Anstee QM; Lawitz EJ; Wai-Sun Wong V; Romero-Gomez M; Kersey K; Li G; Subramanian GM; Myers RP; Djedjos CS; Okanoue T; Trauner M; Goodman Z; Harrison SA
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2552-2560.e10. PubMed ID: 30779990
[TBL] [Abstract][Full Text] [Related]
2. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
Younossi ZM; Anstee QM; Wai-Sun Wong V; Trauner M; Lawitz EJ; Harrison SA; Camargo M; Kersey K; Subramanian GM; Myers RP; Stepanova M
Gastroenterology; 2021 Apr; 160(5):1608-1619.e13. PubMed ID: 33307033
[TBL] [Abstract][Full Text] [Related]
3. Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.
Younossi ZM; Stepanova M; Younossi I; Racila A
Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2093-2100.e3. PubMed ID: 30639779
[TBL] [Abstract][Full Text] [Related]
4. Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
Younossi ZM; Stepanova M; Noureddin M; Kowdley KV; Strasser SI; Kohli A; Ruane P; Shiffman ML; Sheikh A; Gunn N; Caldwell SH; Huss RS; Myers RP; Wai-Sun Wong V; Alkhouri N; Goodman Z; Loomba R
Hepatol Commun; 2021 Jul; 5(7):1201-1211. PubMed ID: 34278169
[TBL] [Abstract][Full Text] [Related]
5. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Harrison SA; Wong VW; Okanoue T; Bzowej N; Vuppalanchi R; Younes Z; Kohli A; Sarin S; Caldwell SH; Alkhouri N; Shiffman ML; Camargo M; Li G; Kersey K; Jia C; Zhu Y; Djedjos CS; Subramanian GM; Myers RP; Gunn N; Sheikh A; Anstee QM; Romero-Gomez M; Trauner M; Goodman Z; Lawitz EJ; Younossi Z; ;
J Hepatol; 2020 Jul; 73(1):26-39. PubMed ID: 32147362
[TBL] [Abstract][Full Text] [Related]
6. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib.
Younossi ZM; Stepanova M; Lawitz E; Charlton M; Loomba R; Myers RP; Subramanian M; McHutchison JG; Goodman Z
Liver Int; 2018 Oct; 38(10):1849-1859. PubMed ID: 29377462
[TBL] [Abstract][Full Text] [Related]
7. The Potential Role of Fatigue in Identifying Patients With NASH and Advanced Fibrosis Who Experience Disease Progression.
Younossi ZM; Stepanova M; Myers RP; Younossi I; Henry L
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):970-977.e1. PubMed ID: 35533993
[TBL] [Abstract][Full Text] [Related]
8. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes.
Younossi Z; Aggarwal P; Shrestha I; Fernandes J; Johansen P; Augusto M; Nair S
JHEP Rep; 2022 Sep; 4(9):100525. PubMed ID: 36039144
[TBL] [Abstract][Full Text] [Related]
9. Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life.
Younossi ZM; Stepanova M; Lawitz EJ; Reddy KR; Wai-Sun Wong V; Mangia A; Muir AJ; Jacobson I; Djedjos CS; Gaggar A; Myers RP; Younossi I; Nader F; Racila A
Am J Gastroenterol; 2019 Oct; 114(10):1636-1641. PubMed ID: 31464743
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
Shelley K; Articolo A; Luthra R; Charlton M
BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
[TBL] [Abstract][Full Text] [Related]
11. Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt.
Alqahtani SA; Yilmaz Y; El-Kassas M; Alswat K; Sanai F; AlZahrani M; Abaalkhail F; AlShaikh M; Al-Hamoudi WK; Nader F; Stepanova M; Younossi ZM;
J Viral Hepat; 2024 Jun; 31(6):300-308. PubMed ID: 38622910
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry.
Younossi ZM; Yilmaz Y; Yu ML; Wai-Sun Wong V; Fernandez MC; Isakov VA; Duseja AK; Mendez-Sanchez N; Eguchi Y; Bugianesi E; Burra P; George J; Fan JG; Papatheodoridis GV; Chan WK; Alswat K; Saeed HS; Singal AK; Romero-Gomez M; Gordon SC; Roberts SK; El Kassas M; Kugelmas M; Ong JP; Alqahtani S; Ziayee M; Lam B; Younossi I; Racila A; Henry L; Stepanova M;
Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2296-2306.e6. PubMed ID: 34768009
[TBL] [Abstract][Full Text] [Related]
14. Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation.
Huber Y; Boyle M; Hallsworth K; Tiniakos D; Straub BK; Labenz C; Ruckes C; Galle PR; Romero-Gómez M; Anstee QM; Schattenberg JM;
Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2085-2092.e1. PubMed ID: 30580090
[TBL] [Abstract][Full Text] [Related]
15. Health-related Quality of Life in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Multi-center UK Study.
Papatheodoridi M; Pallini G; Aithal G; Lim HK; Cobbold J; Plaz Torres MC; Misas MG; Ryan J; Tomlinson J; Allison M; Longworth L; Tsochatzis EA
Clin Gastroenterol Hepatol; 2023 Nov; 21(12):3107-3114.e3. PubMed ID: 37880933
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials.
Anstee QM; Lawitz EJ; Alkhouri N; Wong VW; Romero-Gomez M; Okanoue T; Trauner M; Kersey K; Li G; Han L; Jia C; Wang L; Chen G; Subramanian GM; Myers RP; Djedjos CS; Kohli A; Bzowej N; Younes Z; Sarin S; Shiffman ML; Harrison SA; Afdhal NH; Goodman Z; Younossi ZM
Hepatology; 2019 Nov; 70(5):1521-1530. PubMed ID: 31271665
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
Yamamura S; Nakano D; Hashida R; Tsutsumi T; Kawaguchi T; Okada M; Isoda H; Takahashi H; Matsuse H; Eguchi Y; Sumida Y; Nakajima A; Gerber L; Younossi ZM; Torimura T
J Gastroenterol Hepatol; 2021 Mar; 36(3):629-636. PubMed ID: 32627871
[TBL] [Abstract][Full Text] [Related]
18. Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study.
Yilmaz Y; Toraman AE; Alp C; Doğan Z; Keklikkiran C; Stepanova M; Younossi Z
Aliment Pharmacol Ther; 2023 Jan; 57(2):215-223. PubMed ID: 36369643
[TBL] [Abstract][Full Text] [Related]
19. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
[TBL] [Abstract][Full Text] [Related]
20. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
